Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
156 hedge funds and large institutions have $1.23B invested in Esperion Therapeutics in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 50 increasing their positions, 52 reducing their positions, and 25 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
4% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 25
1% more funds holding
Funds holding: 155 → 156 (+1)
4% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 52
5.5% less ownership
Funds ownership: 105.51% → 100.01% (-5.5%)
38% less capital inflows, than outflows
Capital inflows: $107M | Capital outflows: $174M
52% less call options, than puts
Call options by funds: $46.4M | Put options by funds: $96.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
+$11.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.9M |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$8.9M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$6.54M |
| 5 |
JP Morgan Chase
New York
|
+$6.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AH
Aviva Holdings
New Providence,
Bahamas
|
-$35.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22.5M |
| 3 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$20M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$16.3M |
| 5 |
State Street
Boston,
Massachusetts
|
-$16.3M |
ESPR Hedge Fund Activity: Q4 2018 in Review
156 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2018, worth a combined $1.23B — down 1.7% from $1.25B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ESPR positions and 25 closed out — a net gain of 1 holder — while 50 added to existing stakes and 52 trimmed.
The largest buyer was HSBC Holdings, opening a new position worth an estimated $11.6M. The largest seller was Aviva Holdings, cutting an estimated $35.4M.
- 156 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2018, up from 155 in Q3 2018.
- Funds reported $1.23B of Esperion Therapeutics stock for Q4 2018, down 1.7% quarter-over-quarter.
- 26 funds opened new Esperion Therapeutics positions in Q4 2018 and 25 closed out, a net change of +1 holder.
- The largest Esperion Therapeutics buyer in Q4 2018 was HSBC Holdings, an estimated $11.6M added.
- The largest Esperion Therapeutics seller in Q4 2018 was Aviva Holdings, an estimated $35.4M sold.
Based on aggregated 13F filings for Q4 2018.